Soliton Inc

Soliton — Investor Presentation (March 2021)

27 slides from Soliton's investor presentation, Mar 15, 2021

  1. Slide 1: Rapid Acoustic Pulse Technology

    !"#$%&'(#&)*$+,($"&*-.$/0$102$3452647829$:42;082$<96=455401. Rapid Acoustic Pulse Technology (Nasdaq: SOLY) EXHIBIT 99.1

  2. Slide 2: Forward-Looking Statements

    ! Forward-Looking Statements All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Th

  3. Slide 3: Overview

    " Overview Breakthrough acoustic shockwave device using novel and proprietary Rapid Acoustic Pulse (RAP) technology ! Licensed from MD Anderson Cancer Center ! Induces mechanical disruption to targeted cellular level structures and vacuoles ! No cavitation, heat or collateral tissue damage or pain P

  4. Slide 4: Science Advisory Board

    # Science Advisory Board High profile Key Opinion Leaders Strong podium presence Respected, published researchers

  5. Slide 5: Device and Revenue Strategy

    $ Device and Revenue Strategy Sell consoles Hand piece contains replaceable cartridge Replaceable consumable cartridge for one patient visit “razor and blade” recurring revenue model Images provided by Industrial Design firm; actual product may differ somewhat when the product is launched. There is

  6. Slide 6: Electro-hydraulic shockwave technology and device design

    % ! Electro-hydraulics (arc plasma in saline) utilizes 3000 volts at 3000 amps; creates shockwaves from .25 to 12 MPa @ 100 Hz ! Electronic wave shaping enables very high repetition rate; reduces unwanted frequencies that cause heat and pain ! Custom designed reflector eliminates cavitation, heat, p

  7. Slide 7: Rapid Acoustic Pulse Physical and Biological Effects

    & Hydrophone measurements using an Onda Corporation AIMS III (Acoustic Intensity Measurement System), using HNR-1000 Hydrophone; Z-Wave setup: Z-WavePro set to maximum output (185 mJ), using Z-Wave Handpiece 2.2 Soliton’s Rapid Acoustic Pulse Physical Effects ! ECM/Fibrous Septa disruption (Acoustic

  8. Slide 8: Acoustic ECM Disruption—Breakthrough

    ' Acoustic ECM Disruption—Breakthrough CONTROL – 20X 1 MIN – 20X 2 MIN – 20X 3 MIN – 20X Septa Disruption—Time Dose Response (Source: Control—Tx#26, Pig202 (68659); Test—Tx#63, Day O, Pig 210a. R1-R3 (68659 vs 91940 vs 91939 vs 91900); Head: Omega set at higher power 2800v, 100HZ, 70ms) (Animal Mode

  9. Slide 9: Soliton's Pipeline

    ( Soliton’s Pipeline Indication Pre-Clinical Human POC Pivotal FDA Clearance Commercial Launch Potential Global Market Size Cellulite Reduction 1H21 $4.0B by 2025 Tattoo Removal 1H21 $4.0B by 2023 Keloid and Hypertrophic Scar Reduction 2023 $10.0B by 2025 Skin Laxity Reduction 2024 $6.3B in 2018 Oth

  10. Slide 10: Cellulite FDA Cleared January 2021

    !"#$%&'(#&)*$+,($"&*-.$/0$102$3452647829$:42;082$<96=455401. Cellulite FDA Cleared January 2021

  11. Slide 11: $4B Cellulite Market by 2025

    $4B Market by 2025.* Estimated 38 million US women in our target market * Is indicated in Medical News Today November 30, 2017. ** For illustrative purposes only. There can be no assurance that these assumptions regarding market size, market share or revenue will be achieved. *** Per US census data

  12. Slide 12: Competitive Landscape in Cellulite

    Company Technology Noninvasive Avg Cost # Trmts Long-term Duration Side Effects Patient Satisfaction Syneron Candela RF $1,600 4+ L 60% Cynosure RF & massage 6 L Solta RF $2,475 1 H 67% BTL RF & targeted pressure energy $3,100 4 L 90% Venus Concept RF & pulsed EM fields $2,050 6+ L 62% Soliton Rapid

  13. Slide 13: The Soliton Approach to Cellulite

    The Soliton Approach to Cellulite )" Acoustic Subcision Septa contracts and becomes sclerotic holding portions of the skin with a non-flexible length of septa This results in areas of the skin being pulled down while adjacent sections bulge outward resulting in dimples and ridges Our device emits ra

  14. Slide 14: Pivotal Cellulite Trial Results

    3.41 2.05 2.40 1.47 1.00 1.50 2.00 2.50 3.00 3.50 4.00 Pivotal Cellulite Trial Results Single Treatment at 12 weeks Acoustic Cellulite Release (n=56) Skin Rejuvenation (n=44) 29.6%** 28.5%*** Pre PrePost Post Hexsel Laxity Score (0-3) CSS Score (0-5) Summary: 12-Week Results Pain Score: 2.4 (on a sc

  15. Slide 15: Before and after: Subject 57

    )$ Before 12-WK Pivotal Trial Subject after Single RAP Treatment Subject 57 WEIGHT: +6.4 lbs

  16. Slide 16: Before and after: Subject 62

    )% Before 12-WK Pivotal Trial Subject after Single RAP Treatment Subject 62 WEIGHT: -4.8 lbs

  17. Slide 17: Before and after: Subject 30

    )& Before 12-WK Pivotal Trial Subject after Single RAP Treatment Subject 30 WEIGHT: -0.6 lbs

  18. Slide 18: Before and after: Subject 18

    )' Before 12-WK Pivotal Trial Subject after Single RAP Treatment Subject 18 WEIGHT: -5.2 lbs Courtesy of Dr. Brenda LaTowskyCourtesy of Dr. Brenda LaTowsky

  19. Slide 19: Before and after: Subject 63

    Pivotal Trial Subject after Single RAP Treatment Before 12-WK )( Subject 63 WEIGHT: +0.6 lbs

  20. Slide 20: Before and after: Subject 58

    !* Before 12-WK Pivotal Trial Subject after Single RAP Treatment Subject 58 WEIGHT: +3.4 lbs Courtesy of Dr. Omer IbrahimCourtesy of Dr. Omer Ibrahim

  21. Slide 21: Tattoo Removal: FDA Cleared in 2019

    Tattoo Removal We received clearance from the FDA for the tattoo removal !) FDA Cleared in 2019

  22. Slide 22: $4B Global Tattoo Removal Market by 2023

    $4B Global Market by 2023 5% Market Share = $200M Revenue* Estimated 44 million Americans want some form of tattoo removal * For illustrative purposes only. There can be no assurance that these assumptions regarding market size, market share or revenue will be achieved. ** As demonstrated in our own

  23. Slide 23: Statistically Significant Clinical Results

    !" Statistically Significant Clinical Results *Results presented from the Company’s 2017 clinical trial. Fading percentages were determined by a panel of unaffiliated doctors who reviewed the patient results and graded fading. ! Soliton RAP used in conjunction with existing laser for tattoo removal

  24. Slide 24: Complete removal of treated ink after treatment sessions

    !# Complete removal of treated ink after 3 treatment sessions* Before After 3 Treatments Individual results will vary. For illustrative purposes only. *At each session, treated area was treated with multiple laser passes, with each laser pass followed by a treatment with the RAP device.

  25. Slide 25: Commercialization Pathway

    !$ 2021 2022 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 Brand Development FDA – Device Upgrades Staffing Additions Initial Commercial Launch Sales Force Build Cellulite FDA Clearance This schedule portrays a possible path to commercialization. The remaining impact of COVID-19 on the aesthetic and finan

  26. Slide 26: Key Milestones

    MILESTONE ANTICIPATED TIMING FDA Clearance for Tattoo Removal May 2019 Initiate Cellulite Pivotal Trial Mid 2019 Keloid Scarring POC Trial Mid 2019 FDA Clearance for Gen II RAP Device upgrades Q1 2020 Announce Pivotal Cellulite Results Q2 2020 File FDA Application for Cellulite Q2 2020 Cellulite FDA

  27. Slide 27: Thank you

    !"#$%&'(#&)*$+,($"&*-.$/0$102$3452647829$:42;082$<96=455401. Rapid Acoustic Pulse Technology (Nasdaq: SOLY) Thank you

Soliton — Investor Presentation (March 2021) on 6ix